Evidence map›Paper›PMID 30150789›Full record

ArticleActa pharmacologica Sinica2018

SND p102 promotes extracellular matrix accumulation and cell proliferation in rat glomerular mesangial cells via the AT1R/ERK/Smad3 pathway.

Jin-Lan Xu, Xin-Xin Gan, Jun Ni, De-Cui Shao, Yang Shen, Nai-Jun Miao, Dan Xu, Li Zhou, Wei Zhang, Li-Min Lu

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. RAAS, ACE2 and COVID-19; a mechanistic review.Saudi journal of biological sciences · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. BKInternational journal of endocrinology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jin-Lan XuDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xin-Xin GanDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Jun NiDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
De-Cui ShaoDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yang ShenDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Nai-Jun MiaoDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Dan XuDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Li ZhouDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Wei ZhangDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wzhang@shmu.edu.cn.
Li-Min LuDepartment of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. lulimin@shmu.edu.cn.
Shanghai Medical College of Fudan University · CNWannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SND p102 was first described as a transcriptional co-activator, and subsequently determined to be a co-regulator of Pim-1, STAT6 and STAT5. We previously reported that SND p102 expression was increased in high glucose-treated mesangial cells (MCs) and plays a role in the extracellular matrix (ECM) accumulation of MCs by regulating the activation of RAS. In this study, we further examined the roles of SND p102 in diabetic nephropathy (DN)-induced glomerulosclerosis. Rats were injected with STZ (50 mg/kg, ip) to induce diabetes. MCs or isolated glomeruli were cultured in normal glucose (NG, 5.5 mmol/L)- or high glucose (HG, 25 mmol/L)-containing DMEM. We found that SND p102 expression was significantly increased in the diabetic kidneys, as well as in HG-treated isolated glomeruli and MCs. In addition, HG treatment induced significant fibrotic changes in MCs evidenced by enhanced protein expression of TGF-β, fbronectin and collagen IV, and significantly increased the proliferation of MCs. We further revealed that overexpression of SND p102 significantly increased the protein expression of angiotensin II (Ang II) type 1 receptor (AT1R) in MCs by increasing its mRNA levels via directly targeting the AT1R 3'-UTR, which resulted in activation of the ERK/Smad3 signaling and subsequently promoted the up-regulation of fbronectin, collagen IV, and TGF-β in MCs, as well as the cell proliferation. These results demonstrate that SND p102 is a key regulator of AT1R-mediating ECM synthesis and cell proliferation in MCs. Thus, small molecule inhibitors of SND p102 may be a novel therapeutic strategy for DN.

Indexed as

AnimalsCell ProliferationCollagen Type IVDiabetes Mellitus, ExperimentalDiabetic NephropathiesDown-RegulationEndonucleasesExtracellular MatrixExtracellular Signal-Regulated MAP KinasesFibronectinsFibrosisGene Knockdown TechniquesHEK293 CellsHumansKidneyMaleCollagen Type IVEndonucleasesExtracellular Signal-Regulated MAP KinasesFibronectinsNuclear ProteinsReceptor, Angiotensin, Type 1Smad3 ProteinSmad3 protein, ratSnd1 protein, ratTransforming Growth Factor betaAng II type 1 receptorcell proliferationdiabetic nephropathyERKextracellular matrix accumulationisolated glomerulimesangial cellsSmad3SND p102

Identifiers

PMID30150789
PMCPMC6289350
OpenAlexW2800676308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.